We have developed a completely new antibody pair and ELISpot kits for human IP-10, also known as CXCL10. The antibodies cross-react with rhesus and cynomolgus IP-10, and we can therefore also offer monkey IP-10 ELISpot kits.
Despite its name, “Interferon-γ-induced Protein 10”, IP-10 is secreted not only in response to IFN-γ, but also to TNF-α and IL-1β. This proinflammatory chemokine is secreted by monocytes and has been suggested as an alternative (and perhaps more sensitive) biomarker to IFN-γ for tuberculosis. In addition, high IP-10 levels in plasma have been shown to correlate with severe COVID-19. Interestingly, IP-10 has even been implied in the process of demyelination of the olfactory nerve during COVID-19, suggesting that IP-10 might play a role in the loss of smell during SARS-CoV-2 infection.
Up until now, the scientific community has been limited to the study of IP-10 in plasma/serum using e.g., ELISA. But today we open up the possibility to enumerate IP-10 secreting cells with ELISpot, enabling a more detailed look at the response.
References
- Fisher et al., Elevated IP-10 at the Protein and Gene Level Associates With Pulmonary TB, Front. Cell. Infect. Microbiol. 2022
- Hong et al., Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment, J Infect. 2014
- Whittaker et al., Is IP-10 a Better Biomarker for Active and Latent Tuberculosis in Children than IFNγ?, PLOS ONE 2008
- Ruhwald et al., CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7, Microbes Infect. 2007
- Hayney et al., Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults, J Clin Virol. 2017
- Yang et al., Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J Allergy Clin Immunol. 2020
- Bunprakob et al., IP-10 and complement activation as friend or foe in COVID-19, Int J Immunopathol Pharmacol. 2022
- Chen et al., IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19, Mol Med. 2020
- Oliviero et al., COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?, Neuroscientist. 2021